BP 1249

Drug Profile

BP 1249

Alternative Names: Atopic dermatitis therapy - Bridge Pharma

Latest Information Update: 28 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bridge Pharma
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atopic dermatitis

Most Recent Events

  • 10 Jun 2002 A new agreement between Bridge Pharma and Immune Network has been signed following termination of 50:50 joint venture
  • 15 Feb 2001 BP 1249 has been selected as the lead drug candidate from Bridge Pharma and Immune Network's atopic dermatitis research programme
  • 23 May 2000 Preclinical development for Atopic dermatitis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top